3,4-Methylenedioxymethamphetamine (MDMA/“ecstasy”) is an empathogen that can give rise to increased pleasure and empathy and may effectively treat post-traumatic stress disorder. Although prior research has demonstrated associations between ecstasy use and favorable mental health outcomes, the associations between ecstasy and physical health have largely been unexplored. Thus, the goal of this study was to examine the associations between ecstasy use and physical health in a population-based survey sample.
Method:
This study utilized data from the National Survey on Drug Use and Health (2005–2018), a yearly survey that collects information on substance use and health outcomes in a nationally representative sample of U.S. adults. We used multinomial, ordered, and logistic regression models to test the associations between lifetime ecstasy use and various markers of physical health (self-reported body mass index, overall health, past year heart condition and/or cancer, past year heart disease, past year hypertension, and past year diabetes), controlling for a range of potential confounders.
Results:
Lifetime ecstasy use was associated with significantly lower risk of self-reported overweightness and obesity (adjusted relative risk ratio range: 0.55–0.88) and lower odds of self-reported past year heart condition and/or cancer (adjusted odds ratio (aOR): 0.67), hypertension (aOR: 0.85), and diabetes (aOR: 0.58). Ecstasy use was also associated with significantly higher odds of better self-reported overall health (aOR: 1.18).
Conclusion:
Ecstasy shares protective associations with various physical health markers. Future longitudinal studies and clinical trials are needed to more rigorously test these associations.
BrewertonTDWangJBLafranceA, et al. (2022) MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD. J Psychiatr Res149: 128–135.
2.
BurgMMBrandtCButaE, et al. (2017) Risk for incident hypertension associated with PTSD in military veterans, and the effect of PTSD treatment. Psychosom Med79: 181–188.
3.
ChristensenCHRostronBCosgroveC, et al. (2018) Association of cigarette, cigar, and pipe use with mortality risk in the US population. JAMA Intern Med178: 469–476.
4.
ClarkSDLongMMSchiffmanLG (1999) The mind-body connection: The relationship among physical activity level, life satisfaction, and cognitive age among mature females. J Soc Behav Pers14: 221.
5.
ClemensKJMcGregorISHuntGE, et al. (2007) MDMA, methamphetamine and their combination: Possible lessons for party drug users from recent preclinical research. Drug Alcohol Rev26: 9–15.
6.
ConnorTJHarkinAKellyJP (2005) Methylenedioxymethamphetamine suppresses production of the proinflammatory cytokine tumor necrosis factor-α independent of a β-Adrenoceptor-mediated increase in interleukin-10. J Pharmacol Exp Ther312: 134–143.
7.
CosgroveMPSargeantLAGriffinSJ (2008) Does depression increase the risk of developing type 2 diabetes?Occup Med58: 7–14.
8.
CurranHVRobjantK (2006) Eating attitudes, weight concerns and beliefs about drug effects in women who use ecstasy. J Psychopharmacol (Oxford, England)20: 425–431.
9.
D’AcquistoF (2017) Affective immunology: Where emotions and the immune response converge. Dialogues Clin Neurosci19: 9–19.
10.
DanforthALGrobCSStrubleC, et al. (2018) Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: A randomized, double-blind, placebo-controlled pilot study. Psychopharmacol235: 3137–3148.
11.
DavisAKRosenbergH (2017) Specific harm reduction strategies employed by 3,4-methylenedioxymethamphetmine/ecstasy users in the United States and the United Kingdom. Drug Sci Policy Law. Epub ahead of print 29 May 2017. DOI: 10.1177/2050324517711069.
12.
Dos SantosRGOsórioFLCrippaJAS, et al. (2016) Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): A systematic review of clinical trials published in the last 25 years. Ther Adv Psychopharmacol6: 193–213.
13.
DowneyLALoftisJM (2014) Altered energy production, lowered antioxidant potential, and inflammatory processes mediate CNS damage associated with abuse of the psychostimulants MDMA and methamphetamine. Eur J Pharmacol727: 125–129.
14.
DumontGJHVerkesRJ (2006) A review of acute effects of 3, 4-methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol20: 176–187.
15.
Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults (U.S.) (1998) Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. National Institutes of Health, National Heart, Lung, and Blood Institute.
16.
FeducciaAAJeromeLKlosinskiB, et al. (2019). Breakthrough for trauma treatment: Safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front Psychiatry10: 650.
17.
FernstromJDChoiS (2008) The development of tolerance to drugs that suppress food intake. Pharmacol Ther117: 105–122.
18.
Garcia-RomeuADavisAKErowidF, et al. (2019) Cessation and reduction in alcohol consumption and misuse after psychedelic use. J Psychopharmacol33: 1088–1101.
19.
GorskaAMKamińskaKWawrzczak-BargiełaA, et al. (2018) Neurochemical and neurotoxic effects of MDMA (ecstasy) and caffeine after chronic combined administration in mice. Neurotox Res33: 532–548.
20.
Gouzoulis-MayfrankEDaumannJ (2006) Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: How strong is the evidence for persistent brain damage?Addiction (Abingdon, England)101: 348–361.
21.
GriffithsRRRichardsWAMcCannU, et al. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacol187: 268–283.
HalpinLECollinsSAYamamotoBK (2014) Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life Sci97: 37–44.
24.
HaslamD (2016) Weight management in obesity – past and present. Int J Clin Pract70: 206–217.
25.
HendricksPSCrawfordMSCropseyKL, et al. (2018) The relationships of classic psychedelic use with criminal behavior in the United States adult population. J Psychopharmacol32: 37–48.
26.
HendricksPSThorneCBClarkCB, et al. (2015) Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol29: 280–288.
27.
HollandJ (2001) Ecstasy: The Complete Guide: A Comprehensive Look at the Risks and Benefits of MDMA. Rochester, Vermont: Inner Traditions/Bear & Co.
28.
HuHEatonWWAnthonyJC, et al. (2017) Age of first drunkenness and risks for all-cause mortality: A 27-year follow-up from the epidemiologic catchment area study. Drug Alcohol Depend176: 148–153.
29.
Inoue-ChoiMMcNeelTSHartgeP, et al. (2019) Non-daily cigarette smokers: Mortality risks in the U.S. Am J Prev Med56: 27–37.
30.
Inoue-ChoiMShielsMSMcNeelTS, et al. (2019) Contemporary associations of exclusive cigarette, cigar, pipe, and smokeless tobacco use with overall and cause-specific mortality in the United States. JNCI Cancer Spectr3: pkz036.
31.
JohnsonMWHendricksPSBarrettFS, et al. (2019) Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther197: 83–102.
32.
JonesGLipsonJNockMK (2022) Associations between classic psychedelics and nicotine dependence in a nationally representative sample. Sci Rep12: 10578.
33.
JonesGMNockMK (2022a) Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. J Psychopharmacol36: 57–65.
34.
JonesGMNockMK (2022b) MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults. J Psychopharmacol36: 46–56.
35.
JonesGMNockMK (2022c) Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension. J Psychopharmacol (Oxford, England)36: 66–73.
36.
JonesGMNockMK (2022d) Exploring protective associations between the use of classic psychedelics and cocaine use disorder: A population-based survey study. Sci Rep12: 2574.
37.
JonesGRicardJALipsonJ, et al. (2022) Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample. Sci Rep12: 4099.
38.
KiblerJLJoshiKMaM (2009) Hypertension in relation to posttraumatic stress disorder and depression in the US National Comorbidity Survey. Behav Med34: 125–132.
39.
KolappaKHendersonDCKishoreSP (2013) No physical health without mental health: Lessons unlearned?Bull World Health Organ91: 3–3A.
40.
LaiDWLQinN (2018) Extraversion personality, perceived health and activity participation among community-dwelling aging adults in Hong Kong. PLoS One13: e0209154.
41.
LevineGNCohenBECommodore-MensahY, et al. (2021) Psychological health, well-being, and the mind-heart-body connection: A scientific statement from the American Heart Association. Circulation143: e763–e783.
42.
LevolaJRoseRJMustonenA, et al. (2020) Association of age at first drink and first alcohol intoxication as predictors of mortality: A birth cohort study. Eur J Public Health30: 1189–1193.
43.
LuomaJLearMK (2021) MDMA-assisted therapy as a means to alter affective, cognitive, behavioral, and neurological systems underlying social dysfunction in social anxiety disorder. Front Psychiatry12: 733893.
44.
MassieMJ (2004) Prevalence of depression in patients with cancer. JNCI Monogr32: 57–71.
45.
MedinaKLShearPK (2007) Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: Contributions of polydrug use. Drug Alcohol Depend87: 303–311.
46.
MitchellJMBogenschutzMLiliensteinA, et al. (2021) MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nat Med27: 1025–1033.
47.
MithoeferMCFeducciaAAJeromeL, et al. (2019) MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacol236: 2735–2745.
48.
MithoeferMCGrobCSBrewertonTD (2016) Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA. The Lancet Psychiatry3: 481–488.
49.
MithoeferMCWagnerMTMithoeferAT, et al. (2013) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. Psychopharmacol27: 28–39.
50.
MoraesLJMirandaMBLouresLF, et al. (2018) A systematic review of psychoneuroimmunology-based interventions. Psychol, Health Med23: 635–652.
51.
MorganMJ (2000) Ecstasy (MDMA): A review of its possible persistent psychological effects. Psychopharmacol152: 230–248.
52.
NicholasCRWangJBCokerA, et al. (2022) The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Drug Alcohol Depend233: 109356.
53.
OnaGKohekMMassaguerT, et al. (2019) Ayahuasca and public health: Health status, psychosocial well-being, lifestyle, and coping strategies in a large sample of ritual ayahuasca users. J Psychoactive Drugs51: 135–145.
54.
PacificiRZuccaroPFarréM, et al. (2001) Effects of repeated doses of MDMA (“ecstasy”) on cell-mediated immune response in humans. Life Sci69: 2931–2941.
55.
PacificiRZuccaroPFarréM, et al. (2002) Cell-mediated immune response in MDMA users after repeated dose administration. Ann N Y Acad Sci965: 421–433.
56.
PerkoniggAOwashiTSteinMB, et al. (2009) Posttraumatic stress disorder and obesity: Evidence for a risk association. Am J Prev Med36: 1–8.
57.
RhodesRESmithNEI (2006) Personality correlates of physical activity: A review and meta-analysis. Br J Sports Med40: 958–965.
58.
RiccaVCastelliniGMannucciE, et al. (2009) Amphetamine derivatives and obesity. Appetite52: 405–409.
59.
SaleemiSPennybakerSJWooldridgeM, et al. (2017) Who is ‘molly’? MDMA adulterants by product name and the impact of harm-reduction services at raves. J Psychopharmacol31: 1056–1060.
60.
SimonssonOHendricksPSCarhart-HarrisR, et al. (2021a) Association between lifetime classic psychedelic use and hypertension in the past year. Hypertension77: 1510–1516.
61.
SimonssonOOsikaWCarhart-HarrisR, et al. (2021b) Associations between lifetime classic psychedelic use and cardiometabolic diseases. Sci Rep11: 14427.
62.
SimonssonOSextonJDHendricksPS (2021c) Associations between lifetime classic psychedelic use and markers of physical health. J Psychopharmacol35: 447–452.
63.
StankeviciusDFerraz-de-PaulaVRibeiroA, et al. (2012) 3, 4-methylenedioxymethamphetamine (ecstasy) decreases inflammation and airway reactivity in a murine model of asthma. Neuroimmunomodulation19: 209–219.
64.
SzaboA (2015) Psychedelics and immunomodulation: Novel approaches and therapeutic opportunities. Front Immunol6: 358.
65.
TeixeiraPJJohnsonMWTimmermannC, et al. (2021) Psychedelics and health behaviour change. J Psychopharmacol36: 12–19.
66.
ter BogtTFMEngelsRCMEDubasJS (2006) Party people: Personality and MDMA use of house party visitors. Addict Behav31: 1240–1244.
67.
ThomasFNBurnetteJLHoytCL (2019) Mindsets of health and healthy eating intentions. J Appl Soc Psychol49: 372–380.
68.
United States Department of Health and Human Services (2020) Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality. National Survey on Drug Use and Health. https://datafiles.samhsa.gov/
69.
Vanattou-SaïfoudineNMcNamaraRHarkinA (2012) Caffeine provokes adverse interactions with 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) and related psychostimulants: Mechanisms and mediators. Br J Pharmacol167: 946–959.
70.
VegtingYRenemanLBooijJ (2016) The effects of ecstasy on neurotransmitter systems: A review on the findings of molecular imaging studies. Psychopharmacol233: 3473–3501.
71.
VollenweiderFX (2001) Brain mechanisms of hallucinogens and entactogens. Dialogues Clin Neurosci3: 265–279.
72.
VollenweiderFXGammaALiechtiM, et al. (1998) Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (“Ecstasy”) in MDMA-Naïve Healthy Volunteers. Neuropsychopharmacol19(4): 241–251.
73.
WilsonKEDishmanRK (2015) Personality and physical activity: A systematic review and meta-analysis. Pers Individ Differ72: 230–242.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
